Efficacy and tolerability of finasteride in symptomatic benign prostatic hyperplasia: A primary care study

Clinical Therapeutics

Volumn 19, Issue 2, 1997, Pages 243-258

  Tenover, J Lisa ^a   Pagano, Grace A ^b   Morton, Ann S ^b   Liss, Charles L ^b   Byrnes, Christine A ^b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

benign; finasteride; hyperplasia; prostate; prostatic; urinary symptoms

Indexed keywords

ANDROSTANOLONE; FINASTERIDE; LIPID;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; HUMAN; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRIMARY MEDICAL CARE; PROSTATE HYPERTROPHY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SEXUAL DYSFUNCTION;

EID: 0030916980     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(97)80113-0     Document Type: Article

References (24)

1. Berry SJ, Coffey DS, Walsh PC, et al. The development of human benign prostatic hyperplasia with age. J Urol. 1984;132: 474-478.
2. Jacobsen SJ, Girman CJ, Guess HA, et al. New diagnostic and treatment guidelines for benign prostatic hyperplasia. Potential impact in the United States. Arch Intern Med. 1995;155:477-481.
3. McConnell JD, Barry MJ, Bruskewitz RC, et al. Benign prostatic hyperplasia: Diagnosis and treatment. Clinical Practice Guideline, Number 8. Rockville, Md: Agency for Health Care Policy and Research, US Department of Health and Human Services; 1994. AHCPR Publication No. 94-0582.
4. White JW. The results of double castration on hypertrophy of the prostate. Ann Surg. 1985;25:1-59.
5. Peters CA, Walsh PC. The effect of nafarelin acetate, a luteinizing-hormone-releasing hormone agonist on benign prostatic hyperplasia. NEJM. 1987;317:599-604.
6. Schröder FH, Westerhof M, Bosch JR, et al. Benign prostatic hyperplasia treated by castration or the LH-RH analogue buserelin: A report of 6 cases. Eur Urol. 1987; 12:318-321.
7. Gormley GJ, Stoner E, Bruskewitz RC, et al. The effect of finasteride in men with benign prostatic hyperplasia. NEJM. 1992; 327:1187-1191.
8. The Finasteride Study Group. Finasteride (MK-906) in the treatment of benign prostatic hyperplasia. Prostate. 1993;22: 291-299.
9. Stoner E, the Finasteride Study Group. Three-year safety and efficacy data on the use of finasteride in the treatment of benign prostatic hyperplasia. Urology. 1994; 43:284-294.
10. Lepor H, Stoner E. Long-term results of medical therapies for benign prostatic hyperplasia. Curr Opin Urol. 1995;5:18-24.
11. Moore E, Bracken B, Bremner W, et al. Proscar®: Five-year experience. Eur Urol. 1993;28:304-309.
12. Boyle P, Gould AL, Roehrborn CG. Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: Meta-analysis of randomized clinical trials. J Urol. 1996;48:398-405.
13. Sorva R, Kuusi T, Taskinen MR, et al. Testosterone substitution increases the activity of lipoprotein lipase and hepatic lipase in hypogonadal males. Atherosclerosis. 1988;69:191-197.
14. Marin P, Oden B, Bjorntorp P. Assimilation and mobilization of triglycerides in subcutaneous abdominal and femoral adipose tissue in vivo in men: Effects of androgens. J Clin Endocrinol Metab. 1995; 80:239-243.
15. Barry MJ, Fowler FJ, O'Leary MP, et al. The American Urological Association Symptom Index for benign prostatic hyperplasia. J Urol. 1992;148:1549-1557.
16. Barry MJ, Fowler FJ, O'Leary MP, et al. Measuring disease-specific health status in men with benign prostatic hyperplasia. Measurement Committee of The American Urological Association. Med Care. 1995;33(Suppl 4):AS145-AS155.
17. Epstein RS, Deverka PA, Chute CG, et al. Validation of a new quality of life questionnaire for benign prostatic hyperplasia. J Clin Epidemiol. 1992;45:1431-1445.
18. Steiner PM, Freidel J, Bremner WF, Stein EA. Standardization of micromethods for plasma cholesterol, triglyceride, and HDL-cholesterol with the lipid clinics' methodology. J Clin Chem. 1981;19:850. Abstract.
19. Andersen JT, Ekman P, Wolf H, et al. Can finasteride reverse the progress of benign prostatic hyperplasia? A two-year placebo-controlled study. The Scandinavian BPH Study Group. Urology. 1995;46:631-637.
20. Girman CJ, Kolman C, Liss CL, et al. Effects of finasteride on health-related quality of life in men with symptomatic benign prostatic hyperplasia. Prostate. 1996; 29:83-90.
21. Byrnes CA, Morton AS, Liss CL, et al. Efficacy, tolerability, and effect on health-related quality of life of finasteride versus placebo in men with symptomatic benign prostatic hyperplasia: A community based study. CUSP Investigators. Clin Ther. 1995;17:956-969.
22. Guess HA, Heyse JF, Gormley GJ. The effect of finasteride on prostate-specific antigen in men with benign prostatic hyperplasia. Prostate. 1993;22:31-37.
23. Guess HA, Heyse JF, Gormley GJ, et al. Effect of finasteride on serum PSA concentration in men with benign prostatic hyperplasia. Results from the North American Phase III Clinical Trial. Urol Clin North Am. 1993;20:627-636.
24. Plawker MW, Fleisher JM, Nitti VW, Macchia RJ. Primary care practitioners: An analysis of their perceptions of voiding dysfunction and prostate cancer. J Urol. 1996;155:601-604.